Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Small vessel diseases in a mechanistic perspective: Targets for Intervention Affected pathways and mechanistic exploitation for prevention of stroke and dementia

Descripción del proyecto

Comprender la relación entre el ictus y la demencia

La microangiopatía (SVD, por sus siglas en inglés) cerebral es una afección neurológica frecuente que afecta a los pequeños vasos sanguíneos del cerebro responsables del suministro de oxígeno y nutrientes. En la SVD cerebral, estos vasos pueden estrecharse, bloquearse o debilitarse, lo que reduce el flujo sanguíneo y daña el tejido cerebral circundante, provocando diversos síntomas neurológicos y deterioro cognitivo. El principal objetivo del proyecto SVDs-at-target, financiado con fondos europeos, es comprender el papel de la variabilidad de la presión arterial como factor de riesgo principal en las SVD y descubrir la implicación de la barrera hematoencefálica y la matriz extracelular. El conocimiento de los mecanismos moleculares de la SVD contribuirá al diseño de tratamientos eficaces.

Objetivo

Stroke and dementia rank among the most pressing health issues in Europe. Cerebral small vessel diseases (SVDs) have emerged as a central link between these two major co-morbidities. SVDs account for more than 30% of strokes and at least 40% of dementia cases. They encounter multiple distinct diseases that can be separated based on their underlying genetic defects, risk factors, and clinical presentations. Despite this profound impact on human health, there are no treatments with proven efficacy against SVDs. The applicants have made major progress in identifying key mechanisms involved in SVDs and their co-morbidities. We recently identified blood pressure variability as a major independent risk factor for multiple SVDs, stroke, and dementia and illuminated the roles of the blood brain barrier and the extracellular matrix in small vessel function. We further identified novel molecular pathways (TIMP3, LTBP1, TGFß) that are shared between different SVDs and thus point towards common mechanisms. This EU network, which brings together basic scientists and academic clinicians, will make use of novel animal models and expertly phenotyped patient cohorts to identify key mechanisms common to multiple SVDs and determine how these mechanisms contribute to individual SVDs. We will: i) identify common molecular, cellular, and physiological mechanisms that compromise the function of microvessels in different SVDs; ii) determine how these common mechanistic defects intersect to drive brain damage; and iii) validate the relevance of mechanisms through interventions in experimental systems (isolated microvessels and in vivo) and in patients (exploratory proof of concept trials). Our resources including novel animal models and state-of-the art technologies (e.g. proteomics & ultra-high field MRI) as well as expertise in clinical trials support the feasibility of the approach. In fact, studies by the applicants already revealed novel attractive targets for therapeutic intervention.

Convocatoria de propuestas

H2020-PHC-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-PHC-2015-two-stage

Régimen de financiación

RIA - Research and Innovation action

Coordinador

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Aportación neta de la UEn
€ 975 167,16
Dirección
GESCHWISTER SCHOLL PLATZ 1
80539 MUNCHEN
Alemania

Ver en el mapa

Región
Bayern Oberbayern München, Kreisfreie Stadt
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 975 167,16

Participantes (13)